glp 1 agonist weight loss GLP-1 Agonists For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH What Is GLP-1 and Why

Although rare, associations with nonarteritic anterior ischemic optic neuropathy, pancreatitis, medullary thyroid carcinoma, and acute kidney injury (AKI) have been reported, primarily through pharmacovigilance and case-based evidence

The American Society of Anesthesiologists (ASA) recommends withholding these drugs before surgery, but definitive guidelines remain unclear

The GLP-1 Receptor Agonist market size is expected to reach $18.32 billion in 2030 at a CAGR of 5.4%, driven by rising prevalence of diabetes.

Compare early results with Wegovy and Mounjaro.

Yet, data on their safety and clinical utility during these reproductive windows remain limited

You may still be a candidate for the Fitish Microdosing program, a lower dose option for patients who want a gentler, cosmetic approach